Vistin Pharma ASA (VISTN) - Net Assets

Latest as of June 2025: Nkr294.27 Million NOK ≈ $30.97 Million USD

Based on the latest financial reports, Vistin Pharma ASA (VISTN) has net assets worth Nkr294.27 Million NOK (≈ $30.97 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr421.72 Million ≈ $44.38 Million USD) and total liabilities (Nkr127.45 Million ≈ $13.41 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how resilient are Vistin Pharma ASA's assets to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	Nkr294.27 Million
% of Total Assets	69.78%
Annual Growth Rate	6.53%
5-Year Change	13.63%
10-Year Change	N/A
Growth Volatility	67.46

Vistin Pharma ASA - Net Assets Trend (2016–2024)

This chart illustrates how Vistin Pharma ASA's net assets have evolved over time, based on quarterly financial data. Also explore VISTN total asset value for the complete picture of this company's asset base.

Annual Net Assets for Vistin Pharma ASA (2016–2024)

The table below shows the annual net assets of Vistin Pharma ASA from 2016 to 2024. For live valuation and market cap data, see VISTN company net worth.

Year	Net Assets	Change
2024-12-31	Nkr309.53 Million ≈ $32.57 Million	-4.10%
2023-12-31	Nkr322.77 Million ≈ $33.96 Million	+18.12%
2022-12-31	Nkr273.26 Million ≈ $28.76 Million	-0.95%
2021-12-31	Nkr275.89 Million ≈ $29.03 Million	+1.28%
2020-12-31	Nkr272.40 Million ≈ $28.66 Million	-34.11%
2019-12-31	Nkr413.40 Million ≈ $43.50 Million	+18.50%
2018-12-31	Nkr348.85 Million ≈ $36.71 Million	+190.33%
2017-12-31	Nkr120.16 Million ≈ $12.64 Million	-35.61%
2016-12-31	Nkr186.61 Million ≈ $19.64 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Vistin Pharma ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 324.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	Nkr135.89 Million	43.90%
Other Components	Nkr173.64 Million	56.10%
Total Equity	Nkr309.53 Million	100.00%

Vistin Pharma ASA Competitors by Market Cap

The table below lists competitors of Vistin Pharma ASA ranked by their market capitalization.

Company	Market Cap
Vaziva Sa PA:ALVAZ	$104.58 Million
ALEXANDRIA PANKKIIRILIIKE F:3ZL	$104.59 Million
Farcent Enterprise Co Ltd TW:1730	$104.59 Million
Geodrill Limited TO:GEO	$104.64 Million
Surge Battery Metals Inc V:NILI	$104.50 Million
POSCO-Thainox Public Company Limited BK:INOX	$104.48 Million
CFI Holding SA WAR:CFI	$104.48 Million
Spigen Korea Co. Ltd KQ:192440	$104.48 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Vistin Pharma ASA's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 322,770,000 to 309,529,000, a change of -13,241,000 (-4.1%).
Net income of 62,750,000 contributed positively to equity growth.
Dividend payments of 77,587,000 reduced retained earnings.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	Nkr62.75 Million	+20.27%
Dividends Paid	Nkr77.59 Million	-25.07%
Other Changes	Nkr1.60 Million	+0.52%
Total Change	Nkr-	-4.10%

Book Value vs Market Value Analysis

This analysis compares Vistin Pharma ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 3.21x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 2.05x to 3.21x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2016-12-31	Nkr10.94	Nkr22.40	x
2017-12-31	Nkr6.89	Nkr22.40	x
2018-12-31	Nkr7.87	Nkr22.40	x
2019-12-31	Nkr9.32	Nkr22.40	x
2020-12-31	Nkr6.14	Nkr22.40	x
2021-12-31	Nkr6.22	Nkr22.40	x
2022-12-31	Nkr6.16	Nkr22.40	x
2023-12-31	Nkr7.28	Nkr22.40	x
2024-12-31	Nkr6.98	Nkr22.40	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Vistin Pharma ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 20.27%
The company demonstrates strong efficiency in generating profits from shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 14.62%
• Asset Turnover: 1.11x
• Equity Multiplier: 1.24x
Recent ROE (20.27%) is above the historical average (7.39%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2016	6.92%	7.58%	0.61x	1.50x	Nkr-5.74 Million
2017	58.59%	39.84%	0.76x	1.93x	Nkr58.38 Million
2018	-21.11%	-37.00%	0.40x	1.43x	Nkr-108.51 Million
2019	16.01%	29.14%	0.45x	1.22x	Nkr24.86 Million
2020	-35.59%	-38.30%	0.79x	1.18x	Nkr-124.20 Million
2021	9.05%	8.96%	0.84x	1.21x	Nkr-2.63 Million
2022	-1.73%	-1.64%	0.71x	1.49x	Nkr-32.04 Million
2023	14.13%	10.47%	1.08x	1.25x	Nkr13.32 Million
2024	20.27%	14.62%	1.11x	1.24x	Nkr31.80 Million

Industry Comparison

This section compares Vistin Pharma ASA's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $501,716,000
Average return on equity (ROE) among peers: -0.67%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Vistin Pharma ASA (VISTN)	Nkr294.27 Million	6.92%	0.43x	$104.53 Million
Photocure (PHO)	$501.72 Million	-0.67%	0.47x	$184.23 Million

About Vistin Pharma ASA

OL:VISTN Norway Drug Manufacturers - Specialty & Generic

Market Cap

$104.53 Million

Nkr993.32 Million NOK

Market Cap Rank

#19016 Global

#167 in Norway

Share Price

Nkr22.40

Change (1 day)

+0.90%

52-Week Range

Nkr19.70 - Nkr26.30

All Time High

Nkr28.06